C-L5PAstem cell-derived secretomes, extracellular vesicles, regenerative medicine
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Micregen stem cell-derived secretomes, extracellular vesicles, regenerative medicine
Micregen has developed Secretomix®, a proprietary platform technology for producing cell-free, stem cell-derived secretome therapeutic products. Its approach harnesses paracrine factors including miRNA, extracellular vesicles, exosomes, proteins and growth factors to target degenerative and underdevelopment conditions. The company describes its products as scalable, allogeneic, off-the-shelf biologics intended to modulate inflammation, cellular senescence, intercellular communication, stem cell exhaustion and autophagy.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Micregen — Far from goals · Bottom quartile. Derived deterministically from 1 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic